Overview of Fosfomicina Stada

Quick Facts

Property	Description
Active ingredient	Fosfomycin trometamol
Form	Granules for oral solution (in single-dose sachet)
Pharmacological class	Antibiotic, Antimicrobial agent
General purpose	Anti-infective treatment (bactericidal action)
Origin	Synthetic compound

What Type of Medicine is Fosfomicina Stada?

Fosfomicina Stada is a prescription medication fundamentally defined as an antibiotic and a broad-spectrum antimicrobial agent. Its general purpose is to function as an anti-infective treatment, countering the proliferation of susceptible bacteria. The compound belongs to the high-level pharmacological class of antibacterials, distinguished by a unique mode of action. The value of this unique structure in therapeutic settings is recognized. This information confirms its role as a tool in microbial defense, particularly in contexts where alternative agents face microbial resistance.

Composition: Active Ingredient and Origin

The foundation of this medicine is the active ingredient Fosfomycin, primarily delivered as the salt Fosfomycin trometamol in the oral preparation. Fosfomycin is classified as a phosphonic acid derivative and is a wholly synthetic compound. Fosfomicina Stada is supplied as granules for oral solution or a dry powder contained within a single-dose sachet, designed for the oral route of administration upon reconstitution with an aqueous vehicle. The salt formulation is characterized by chemical stability and high oral bioavailability, ensuring the Fosfomycin compound is efficiently delivered for its intended antibacterial treatment.

Core Action and Purpose of Fosfomycin

The Fosfomycin compound acts as a bactericidal agent, meaning its function is to actively kill susceptible bacteria. Its unique mechanism of action involves disrupting the foundational structure of the bacterial cell. This action is achieved by irreversibly inhibiting a vital early stage of the bacterial cell wall synthesis. This profound disruptive action on the cell's structural integrity makes the agent clinically recognized for its ability to effect prompt microbial eradication in various anti-infective scenarios. This therapeutic capability establishes its place among systemic antimicrobials.

What side effects are possible with Fosfomicina Stada?

Possible Side Effects and Safety Information

The following information details the officially documented adverse reactions and safety considerations for Fosfomicina Stada, as classified in government regulatory sources. Side effects are organized by how often they occur and by the body system affected.

Frequency-Classified Adverse Reactions

Adverse reactions are classified into categories based on frequency observed during clinical data:

Very Common (Affects 1 in 10 or more people): Headache, dizziness.
Common (Affects up to 1 in 10 people): Diarrhea, nausea, indigestion, vulvovaginitis, infections of the upper respiratory tract.
Uncommon (Affects up to 1 in 100 people): Rash, urticaria (hives), pruritus (itching), vomiting, abdominal pain, asthenia (weakness), paresthesia (tingling), increase in liver enzymes (transaminases, alkaline phosphatase).

Serious and Clinically Significant Reactions

Certain severe reactions have been reported, although their frequency is considered Not Known (cannot be estimated from the available data). These reactions are critical safety concerns and include:

Anaphylactic Shock and other severe hypersensitivity reactions, such as angioedema.
Clostridioides difficile-associated colitis, a severe and potentially life-threatening type of diarrhea that can occur with the use of antibiotics.

Safety Considerations and Restrictions

Official safety profiles highlight specific situations requiring caution:

Renal Impairment: Caution is advised for patients with severe renal impairment (creatinine clearance below 10 mL/min), as this can lead to the accumulation of the medicine in the body.
Elderly Patients: Monitoring is recommended in the elderly due to the increased probability of reduced kidney function related to age.
Drug Interactions: The medicine may interact with metoclopramide, potentially reducing the concentration of Fosfomicina Stada in the body. It may also interfere with the efficacy of live bacterial vaccines (e.g., BCG or Cholera vaccine).

Overdose and Emergency Response

Overdose and when to seek help

The regulatory guidance for an overdose of Fosfomicina Stada (Fosfomycin trometamol) is centered on managing documented clinical and physiological effects, noting that experience with the oral formulation overdose is limited. Overdose may manifest with documented signs and symptoms including somnolence, hypotonia, vestibular loss, and impaired hearing. Furthermore, sensory changes such as a metallic taste and a general decline in taste perception have been reported.

Overdosage is associated with the potential for significant physiological findings, including electrolyte disturbances, thrombocytopenia, and hypoprothrombinemia. Immediate medical attention is necessary, as the patient must be monitored, with specific attention to plasma/serum electrolyte levels, to manage these physiological disturbances.

Treatment is strictly defined in regulatory documents as symptomatic and supportive. Regulatory guidelines specify that rehydration is recommended to promote the urinary elimination of the active substance. There is no specific antidote documented in the official prescribing information; however, the active substance is known to be effectively cleared from the body by haemodialysis.

Therapeutic Uses of Fosfomicina Stada

What Fosfomicina Stada Treats: Main Uses and Benefits

The primary role of this anti-infective agent is applied across therapeutic domains involving localized bacterial presence in the urinary tract. The medication helps treat infections of the urinary tract and cystitis. The therapeutic approach is relevant for conditions associated with bacterial presence, providing support that helps ease the overall symptom burden.

This agent is commonly used across conditions characterized by periods of heightened symptoms such as acute uncomplicated cystitis. It is applied when symptom clusters including dysuria (painful, burning urination), urinary urgency, and frequency, become disruptive. The therapeutic scope includes conditions such as acute uncomplicated cystitis, asymptomatic bacteriuria in pregnant individuals, and prophylaxis to minimize risk prior to urological procedures.

This therapeutic focus supports the patient during difficult episodes by easing distress and may assist with managing infection-related risks in specific contexts. The intervention is relevant for easing symptoms that interfere with daily comfort in contexts involving inflammatory or irritative processes.

Quick Fact: Relief for Acute Discomfort
Primary Symptom Focus	Micturition pain, urgency, and frequency
Main Use Scenario	Acute, uncomplicated lower urinary tract infection
Patient Benefit	Supports comfort and assists with maintaining functional stability

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Fosfomicina Stada?

Eligibility for Fosfomicina Stada (Fosfomycin trometamol) is strictly defined by regulatory documents, focusing on patient status and specific infection type.

Contraindications and Absolute Exclusions

Classification	Population/Condition
Contraindicated	Patients with known serious hypersensitivity to fosfomycin or its excipients.
Not Indicated	Patients with Pyelonephritis, Perinephric Abscess, or other complicated UTIs.

Restricted and Conditional Use

Eligibility is limited for certain groups based on regulatory caution or lack of established data:

Pediatric Use: Safety and effectiveness have not been established for children 12 years of age and under.
Renal Function: Use is not recommended in patients with severe renal impairment (e.g., Creatinine Clearance < 10 mL/min). Excretion is significantly decreased with reduced kidney function.
Pregnancy and Lactation: Use is restricted; it should be used only if clearly needed as the drug crosses the placental barrier and is excreted in human milk.
General Use: The medicine is primarily indicated for uncomplicated cystitis in women and adolescent females, but is also permitted for prophylaxis in men undergoing specific urological procedures.

What should I know about interactions with other medicines?

The interaction profile for Fosfomicina Stada is defined by pharmacokinetic and pharmacodynamic constraints documented in official regulatory sources.

Exposure-Altering Interactions

A significant pharmacokinetic interaction is documented with Metoclopramide and other medicinal products that increase gastrointestinal motility. Co-administration with these agents is restricted because they officially lower the serum concentrations and reduce the urinary excretion of fosfomycin. This reduction in systemic exposure can affect the drug's action. The drug's label also notes that Cimetidine does not affect the drug's pharmacokinetics.

Food and Timing Restrictions

Official information states that ingestion with food reduces the drug's oral bioavailability and peak plasma levels. This pharmacokinetic effect leads to a timing-based rule that requires the medicine to be taken on an empty stomach or separated from meals by approximately two to three hours.

Pharmacodynamic and Restriction Notes

The regulatory profile includes a formal restriction concerning co-administration with Live Bacterial Vaccines (such as the cholera vaccine), which is based on documented pharmacodynamic antagonism. An additional caution exists for Oral Anticoagulants, where reports of altered International Normalized Ratio (INR) are noted in the context of antibiotic use. Furthermore, official labeling notes that in the presence of renal impairment, the excretion and clearance of fosfomycin are significantly decreased, representing a population-specific consideration for systemic exposure.

Mechanism of Action

The mechanism of Fosfomicina Stada involves the targeted disruption of the bacterial cell's core construction mechanism, resulting in bacterial cell lysis.

Unique Cell Wall Precursor Blockade

This domain covers the molecular target and the inhibitory cascade. Fosfomycin acts as an irreversible inhibitor of the bacterial enzyme MurA (UDP-N-acetylglucosamine enolpyruvyl transferase). By forming a permanent covalent bond with this key enzyme, the drug blocks the synthesis of the essential building blocks (N-acetylmuramic acid) required for the rigid peptidoglycan layer, resulting in an immediate cessation of the cell wall construction process.

Bactericidal Lysis via Structural Failure

This domain links the molecular inhibition to the final physiological consequence. Because the structural integrity of the bacterial cell wall cannot be maintained or repaired, the microbe is unable to withstand internal osmotic pressure. This leads to the physical breakdown and rupture of the cell—a bactericidal action that results in the physiological consequence of microbial lysis. The drug's reliance on bacterial GlpT and UhpT transport systems for entry is an essential part of initiating this entire destructive cascade.

Dosage and Administration Information

How to Use Fosfomicina Stada: Official Administration Guidelines

Fosfomicina Stada (fosfomycin trometamol) is an oral preparation supplied as granules for solution, and its administration is defined by a strict, short-course regimen.

Administration Protocol and Dosing

Administration Scope	Detail
Dosing Schedule	For Acute Uncomplicated Cystitis, the standard regimen is a single dose of 3 g fosfomycin. A fixed two-dose regimen (3 g pre-procedure, 3 g post-procedure) is specified for perioperative antibiotic prophylaxis in certain urological procedures, such as transrectal prostate biopsy.
Preparation Requirements	The contents of the sachet must be fully dissolved in a glass of water (e.g., 3–4 ounces) before consumption. The solution must be taken immediately after preparation; the granules must not be swallowed in dry form.
Timing in Relation to Meals	The dose is typically administered on an empty stomach (approximately 2–3 hours before or after a meal) to minimize any reduction in the rate and extent of systemic absorption.

Procedural and Population Rules

Instruction Classifications	Detail
Frequency Pattern	A single course is indicated for uncomplicated cystitis.
Age-Group Rules	The single dose is generally not recommended for children under 12 years of age. No dose adjustment is typically necessary for older adults (geriatric patients).
Procedural Conditions	The dose is preferably administered before bedtime and after emptying the urinary bladder. It is explicitly constrained that only one single dose is indicated for the treatment of a single episode of acute uncomplicated cystitis.

These instructions define the standardized, short-duration administration protocol, mandating the precise preparation and timing for the oral dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus / Mechanism

Research explored the drug's interaction with UDP-N-acetylglucosamine enolpyruvyl transferase (MurA). This enzyme is essential for the initial step in the synthesis of the bacterial cell wall. Studies examined whether this binding was associated with changes in the cell wall synthesis process, which is critical for bacterial survival.

Clinical Trials in Urinary Tract Infections (UTIs)

Fosfomycin tromethamine is an established agent primarily studied for use in uncomplicated urinary tract infections (UTIs). Controlled trials have historically evaluated a single-dose regimen for this indication.

Uncomplicated Cystitis Studies

A series of clinical trials evaluated the performance of a single oral dose compared to placebo or other antibiotics in adult women with acute, uncomplicated cystitis (bladder infection).

Efficacy Endpoints: Primary research endpoints focused on the achievement of microbiological cure (elimination of the responsible bacteria from the urine) and clinical success (resolution of UTI symptoms).
Recent Research: Recent research has focused on the drug's activity against difficult-to-treat, multi-drug resistant (MDR) bacteria, often exploring its use in more complex or systemic infections, including those in the respiratory tract, sometimes in combination with other antibiotics.

Safety and Dosing Research

Safety Profile

Safety data collected across multiple clinical trials was analyzed to understand the drug's side-effect profile. Common adverse events reported in these studies include gastrointestinal disturbances (such as nausea, diarrhea, and stomach pain) and headache.

Dosing Regimens

Research protocols often explore the lowest possible dose that may be associated with a change in bacterial clearance, with a focus on potential adverse effects. Studies have evaluated different starting and maintenance dosages, particularly in non-UTI settings or against MDR pathogens.

Summary for Interested Individuals

The evidence reviewed here describes what studies have investigated regarding this treatment and its research profile. A healthcare professional can discuss how these study findings may apply to an individual. Individuals may seek information from a qualified healthcare professional.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Fosfomicina Stada (FAQ)

Q: What is Fosfomicina Stada used for besides bladder infections?

According to official product information, the primary use for the oral formulation is the treatment of acute, uncomplicated bladder infections (cystitis). Regulatory documents describe its use for antibiotic prophylaxis, which is the prevention of infection before specific urological procedures in men.

Q: Is Fosfomicina Stada the same type of medicine as antibiotics I've taken before?

Fosfomicina Stada is classified as a phosphonic acid derivative, which is a unique chemical structure among antimicrobials. Official information indicates that it works differently from most other common antibiotics by blocking an early stage of bacterial cell wall synthesis. Due to this unique action, the drug is not generally considered to be structurally or chemically related to many other common classes of antibiotics.

Q: How quickly should Fosfomicina Stada start working after I take it?

The medicine is classified as a bactericidal agent, meaning its primary function is to actively kill susceptible bacteria. Official information about its mechanism of action states that the disruptive action on the cell wall synthesis begins as soon as the compound reaches the target site.

Q: Are there specific foods or drinks that should be avoided when using Fosfomicina Stada?

Official information emphasizes that the medicine must be taken on an empty stomach, which means approximately two to three hours before or after a meal. This timing is necessary to avoid a reduction in the drug's absorption. Regulatory documents do not specify any particular foods that must be avoided, only the timing relative to consumption.

Q: What is the difference between Fosfomicina Stada and other common UTI medicines?

The drug is distinct because of its unique mechanism of action, which involves blocking a specific enzyme (MurA) essential for bacterial cell wall synthesis. Regulatory and scientific reviews indicate that this action means the medicine is not structurally or chemically related to most other common antibiotics used for urinary tract infections.

Q: Is Fosfomicina Stada available over the counter in some countries?

Official documents from major regulatory bodies classify Fosfomicina Stada as a prescription-only medication. This means it requires a prescription from a qualified healthcare professional to be obtained.

Q: Is it common to feel tired after taking Fosfomicina Stada?

The side effect asthenia, or weakness/tiredness, is noted in the official product information. It is listed as an uncommon adverse reaction, meaning it is reported in up to 1 in 100 people, as observed in clinical data.

Q: What should I know about taking Fosfomicina Stada if I have diabetes?

Official documents state that the medicine contains sucrose (sugar) as one of the inactive ingredients. However, no specific guidance related to blood sugar management for diabetic patients is included in the official product information.

Q: Does taking Fosfomicina Stada affect blood sugar levels?

Official documents only detail the composition of the product, which includes sucrose (sugar) as an inactive ingredient. The labeling does not contain statements regarding direct effects on blood sugar levels.

Q: Can Fosfomicina Stada cause problems with my liver?

The medicine is primarily cleared from the body via the kidneys, rather than through the liver. Official safety profiles note that an increase in liver enzymes (transaminases, alkaline phosphatase) is an uncommon side effect.

Q: Is Fosfomicina Stada considered a 'broad spectrum' antibiotic?

Yes, Fosfomicina Stada is classified in regulatory documents as a broad-spectrum antimicrobial agent. This means it is active against a wide range of susceptible bacteria, performing a bactericidal action (killing bacteria) by disrupting the bacterial cell wall.

Q: Can people with a history of allergies take Fosfomicina Stada?

The medicine is contraindicated (not recommended for use) in patients who have a known serious hypersensitivity, or allergy, to the active ingredient fosfomycin or to any of its excipients used in the product formulation.

Q: Can children or teenagers use Fosfomicina Stada?

Official information indicates that the single dose regimen is generally not recommended or approved for children younger than 12 years of age. Its use is, however, indicated for adolescent females who are 12 years and older.

Q: Does Fosfomicina Stada interact with antacids or heartburn medication?

Regulatory information states that taking the medicine with food reduces its absorption, which is why it must be taken on an empty stomach. Certain substances, like antacids, may also affect how the medicine is absorbed, but official labeling does not detail specific interaction warnings for antacids.

Q: What happens if I miss the specific time I was supposed to take Fosfomicina Stada?

Fosfomicina Stada for uncomplicated cystitis is specifically administered as a single dose. Because of this, the concept of a 'missed dose' that applies to scheduled, multi-day regimens is generally not applicable to this specific usage.

Q: What distinguishes Fosfomicina from other forms of the drug?

The active ingredient Fosfomycin is delivered in different salt forms, such as Fosfomycin trometamol (used in this oral, single-dose product) and fosfomycin disodium (used in injectable products). These different formulations are approved for different indications and may have different pharmacokinetic properties (how they are absorbed and eliminated).

Q: Is Fosfomicina Stada effective against infections resistant to other antibiotics?

Studies noted in regulatory reviews have focused on the drug's activity against multi-drug resistant (MDR) bacteria. Evidence indicates that the drug's unique mechanism of action is explored for activity against some strains resistant to other antibiotics.

Q: Are there any studies comparing different formulations of fosfomycin?

Regulatory review documents have noted the differences in the properties of various salt formulations of fosfomycin. Official information indicates that data regarding effectiveness and safety may not be directly extrapolated between them due to differences in absorption.

Q: Is the sensation of dizziness a common side effect of Fosfomicina Stada?

Yes, dizziness is classified in the official product labeling as a very common adverse reaction. This frequency means that the effect is expected to occur in 1 out of every 10 people or more who take the medicine.

Q: Can Fosfomicina Stada be used in patients with known liver disease?

Specific restrictions for liver disease are not detailed in the official safety information in the same way as restrictions for severe kidney impairment. The medicine is primarily cleared from the body via the kidneys, rather than through the liver.

Q: Is Fosfomicina Stada known for causing fungal infections or yeast infections?

Official side effect information lists vulvovaginitis (vaginal inflammation) as a common side effect, meaning it affects up to 1 in 10 people. This condition is a general term that may be related to the development of fungal or yeast infections.

Q: Can Fosfomicina Stada interact with blood thinners like warfarin?

Official labeling includes caution for the class of drugs known as Oral Anticoagulants. This is due to reports of an altered International Normalized Ratio (INR), which is a common measure of blood clotting. The medicine may interact with this class of drugs.

Q: Can Fosfomicina Stada be used to treat infections in men?

The medicine is primarily indicated for uncomplicated cystitis in women and adolescent females. For men, its regulatory use is generally limited to antibiotic prophylaxis in specific urological procedures. Its use for the treatment of acute infections in men is not the primary indication described in regulatory documents for this formulation.

How should Fosfomicina Stada be stored and disposed of?

How to Store and Dispose of Fosfomicina Stada?

Official Storage Conditions

Fosfomicina Stada granules must be stored at controlled room temperature, with a typical range of 15 C to 30 C (59 F to 86 F). The product must be kept from freezing, stored away from heat, and protected from both light and moisture. Always store the medicine in its original package (sachet/carton) and do not use it after the stated expiration date.

Handling and Safety Requirements

Per regulatory mandate, this medicine must be kept out of the sight and reach of children. Once the granules are dissolved in water to form the solution, it must be consumed immediately; the prepared solution is not intended for storage.

Disposal Instructions

To protect the environment, unused or expired Fosfomicina Stada must not be thrown away with household trash or disposed of via wastewater. Patients should return the unused medicine to a pharmacist for proper discard, according to local pharmaceutical waste requirements.

Fosfomicina Stada